CareDx appoints Bryan Riggsbee to board as Audit Committee chair, effective March 11

CareDx, Inc.

Riggsbee previously CFO of Myriad Genetics (2014–2024) and held senior finance roles at LabCorp and GE.
He will serve as Chair of the Audit and Finance Committee, succeeding George Bickerstaff who remains on the committee.
Annual cash retainer of $45,000 for Board service plus $20,000 for Audit Committee chair, both payable quarterly.
Initial equity grants of $200,000 fair value (options and RSUs) contingent on stockholder approval of new equity plan.
No family relationships or related party transactions; standard indemnification agreement entered.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

R. Bryan Riggsbee

Director

CDNA · CareDx, Inc.

Effective: 2024-03-11
Filed: March 11, 2024, 7:59 PM ET

On March 9, 2024, the board of directors (the “Board”) of CareDx, Inc. (the “Company”) appointed R. Bryan Riggsbee as a Class II director of the Company, effective March 11, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

R. Bryan Riggsbee was appointed as Director at CareDx, Inc..

Action: appointed
Role: Director

Exact text from the filing

On March 9, 2024, the board of directors (the “Board”) of CareDx, Inc. (the “Company”) appointed R. Bryan Riggsbee as a Class II director of the Company, effective March 11, 2024.

View on SEC.gov

CareDx, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-064783

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.